Investors are more bearish on Peregrine Pharmaceuticals Inc. lately at least if you consider the change in short interest. The stock had a rise in short interest from August 15, 2017 to August 31, 2017 of 12.77%. Short interest grew 250 over that timeframe. The days to cover decreased to 0.0 and the percentage of shorted shares is 0.00% as of August 31.
The company is up by 0.90%% since yesterday’s close of 21.42. Peregrine Pharmaceuticals Inc. announced a dividend that will be paid on Monday October 2nd, 2017. The dividend payment will be $0.655 per share for the quarter or $2.62 on an annualized basis. This dividend represents a yield of $12.13 which is the dividend as a percentage of the current share price. The ex-dividend date has been established as Friday the 15th of September 2017.
Shares are trading at $21.61 just below $22.01, the stock’s 50 day moving average and barely below the 200 day moving average of $21.96. The 50 day moving average was down by -1.81% whereas the 200 day moving average was down $-0.35 or -1.59%.
Peregrine Pharmaceuticals, Inc. (Peregrine), launched on September 25, 1996, is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is involved in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is involved in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. The Company delivers pharmaceutical products through its contract manufacturing business and through licensing its development-stage immunotherapy products. The Business’s subsidiary is Avid Bioservices, Inc. (Avid)..